Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status

Abstract excerpt

As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment of ovarian cancer, the five-year survival rate of patients is still less than 50%. Based on the concept of synthetic lethality, poly (ADP- ribose) polymerase (PARP) inhibitors target tumor cells with defects in homologous...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy
• Share to Toxin Mechanisms and Immunotoxins